Key result
Direct oral anticoagulants (DOACs) have shown promising results in Phase III clinical trials for post-operative venous thromboembolism prophylaxis.
Why the study?
Traditional post-operative thromboprophylaxis with heparin and warfarin is limited by narrow therapeutic ranges, interactions, and monitoring requirements, prompting evaluation of direct oral anticoagulants.
Do direct oral anticoagulants (DOACs) prevent post-operative venous thromboembolism compared to traditional anticoagulants?
Do direct oral anticoagulants (DOACs) prevent post-operative venous thromboembolism compared to traditional anticoagulants?
This review highlights the pharmacological profile and promising clinical trial data for DOACs as an alternative to heparin and warfarin in post-operative VTE prophylaxis.
Supports further DOAC evaluation for post-operative VTE; leaves open adoption pending head-to-head trials versus standard agents.
Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.
No takes yet. Share an insight, caveat, or question.
Tun et al. (2022) conducted a review in Post-operative Venous Thromboembolism (VTE). Direct oral anticoagulants (DOACs) vs. Heparin and warfarin was evaluated. Direct oral anticoagulants (DOACs) have shown promising results in Phase III clinical trials for post-operative venous thromboembolism prophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: